CONTEXT: Presentation of RWD on Mavacamten in obstructive hypertrophic cardiomyopathy by MS at the ACC annual scientific session being held virtually this year. BMS following an increasing trend od presenting Continue Reading
CONTEXT: As the parent of a son who is still undiagnosed but probably has a Fragile X like syndrome, this news is extremely heartening. To see Real-World Data being used Continue Reading
CONTEXT: Another commercial announcement from Verantos. Regular readers will remember them inking a deal back in March with Amgen to launch an advanced RWE program focused on “high-validity” observational studies. Continue Reading
CONTEXT: I know we are preaching to the converted, but great to see the NEJM publishing a CDC study that underlines how important RWE can be in guiding decisions, even Continue Reading
CONTEXT: This is exactly the kind of article that the big data companies don’t want you reading. If we all start reading terms and conditions on smart products or being Continue Reading
CONTEXT: Another RWR study showing deficiencies in available biomarker testing, this time in Chronic lymphatic leukaemia patients. Biomarker driven care will give better outcomes for those patients with specific mutations Continue Reading
CONTEXT: This is exactly the kind of article that the big data companies don’t want you reading. If we all start reading terms and conditions on smart products or being Continue Reading
CONTEXT: A different approach to spotting early onset dementia, utilising driving behaviour from a 4 year period in the US. As a long-term advocate of better diagnostic tools in dementia Continue Reading
CONTEXT: Commercial announcement of a tie up between TriNetX and Takeda to develop the latter’s use of RWD in their overall trail design strategy. IMPACT: Low READ TIME: 1 min Continue Reading
CONTEXT: “Data monetisation in the Med Tech environment”. I have to be honest – I’ve read this article twice and still not entirely sure what this actually means in real Continue Reading
